Comment: This still reads like an advertisement. To get an idea of the kind of tone we're looking for in an article like this, have a look at Miami Valley Hospital South. Agtx (talk) 19:40, 12 July 2015 (UTC)
Dana-Farber / Boston Children’s Cancer and Blood Disorders Center is a hematology and oncology treatment and research center in Boston, Massachusetts. It combines the resources of Boston Children’s Hospital and Dana-Farber Cancer Institute . The center provides care for children and young adults with cancers and blood diseases.
In 2015-16, U.S. News & World Report ranked Dana-Farber/Boston Children's the top pediatric cancer center in the nation.. Both Dana-Farber and Boston Children’s Hospital are Harvard-affiliated research and teaching centers and both are continually awarded Magnet status by the American Nurse Credentialing Center. 
Dana-Farber/Boston Children’s was founded in 1947 by Sidney Farber, MD . It was originally called the Children’s Cancer Research Foundation. Dana-Farber/Boston Children’s is involved in research on topics including pediatric precision medicine, gene therapy, vaccine therapy and immunotherapy. At any given time, Dana-Farber / Boston Children’s is typically accepting patients to over 100 clinical trials.
• 1932 – At Boston Children’s Hospital, Dr. Louis Diamond characterizes Rh disease, in which a fetus's blood is incompatible with its mother's. Dr. Diamond later develops exchange transfusion to treat the disease.
• 1947 – Dr. Sidney Farber and his team of clinicians and laboratory scientists are the first to use chemotherapy to treat cancer; they achieve the world’s first successful remission of acute lymphoblastic leukemia. The same year, Dr. Sidney Farber founds the Children's Cancer Research Foundation (which later became the Dana-Farber Cancer Institute), and he develops the first research program in chemotherapy for children with cancer.
• 1955 – Dr. Sidney Farber and colleagues achieve the first remissions in Wilms tumor of the kidney, a common form of childhood cancer. By employing the antibiotic actinomycin D in addition to surgery and radiation therapy, they boost cure rates from 40 to 85 percent.
• 1976 – Drs. David Nathan and Blanche Alter develop an in-utero diagnostic test for thalassemia, a serious inherited blood disorder.
• 1976 – Drs. David Nathan, Susan Shurin, and Richard Propper develop parenteral desferrioxamine as a therapy for iron overload (toxicity) in thalassemia and related blood conditions.
• 1977 – Drs. Emil Frei lll and Norman Jaffe use pre-operative chemotherapy to facilitate the world's first limb-salvage surgeries by Dr. Hugh Watts for children with osteosarcoma. This leads to increased cure rates and improved quality of life.
• 1984 – Drs. David Nathan and Orah Platt discover that hydroxyurea raises fetal hemoglobin. Hydroxyurea quickly becomes – and currently still is – the best therapy for sickle cell anemia.
• 1984 – Dr. David Williams develops retroviral vectors for the introduction of genes into hematopoietic stem cells, the technique that lays the ground work for gene therapy.
• 1986 – Dr. Stuart Orkin and his research team develop the technique of positional cloning to identify the genes responsible for chronic granulomatous disease.
• 1986 – Stephen Friend discovers and clones the recessive oncogene, Rb.
• 1997 – Drs. Cameron Trenor, Mark Fleming and Nancy Andrews discover and clone the first iron transporter.
• 1999 – Dr. Todd Golub first uses gene expression microarrays to differentiate cancers.
• 1994-2001 – Dr. Alan D’Andrea describes many of the genes in the Fanconi anemia pathway, including how they function and interact with each other and with other DNA repair pathways.
• 2008 – Drs. Vijay Sankaran and Stuart Orkin discover that the fetal hemoglobin to adult hemoglobin switch is controlled by the BCL11A transcription factor. This factor can reawaken red blood cells' ability to produce a fetal form of hemoglobin (HbF) that can compensate for the lack of functional adult hemoglobin. This solves a decades-old problem in hematology and has important implications for the treatment of sickle cell disease and thalassemias.
• 2008 – Dr. George Daley discovers how to reprogram human somatic cells to pleuripotent stem cells with defined transcription factors.
• 2009 – Drs. George Daley and Richard Gregory show that the microRNA, Lin 28, plays an important role in germ cell development and cancer.